1. Home
  2. NUS vs ASMB Comparison

NUS vs ASMB Comparison

Compare NUS & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nu Skin Enterprises Inc.

NUS

Nu Skin Enterprises Inc.

HOLD

Current Price

$10.81

Market Cap

469.0M

Sector

Health Care

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$26.22

Market Cap

499.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUS
ASMB
Founded
1984
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
469.0M
499.8M
IPO Year
1996
2010

Fundamental Metrics

Financial Performance
Metric
NUS
ASMB
Price
$10.81
$26.22
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$43.40
AVG Volume (30 Days)
467.6K
105.6K
Earning Date
02-12-2026
03-19-2026
Dividend Yield
2.29%
N/A
EPS Growth
N/A
N/A
EPS
2.20
N/A
Revenue
$1,560,391,000.00
$37,191,000.00
Revenue This Year
N/A
$33.33
Revenue Next Year
$2.12
N/A
P/E Ratio
$4.76
N/A
Revenue Growth
N/A
31.30
52 Week Low
$5.32
$7.75
52 Week High
$14.62
$39.71

Technical Indicators

Market Signals
Indicator
NUS
ASMB
Relative Strength Index (RSI) 49.87 37.11
Support Level $10.24 $25.14
Resistance Level $10.80 $30.34
Average True Range (ATR) 0.38 1.73
MACD -0.07 0.00
Stochastic Oscillator 35.86 16.68

Price Performance

Historical Comparison
NUS
ASMB

About NUS Nu Skin Enterprises Inc.

Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: